MCC-135通过降低NCX1表达的调节来产生抗和神经保护作用,以减少海马体内细胞内过载
Chaoning Liu1, Min He1, Rida Li1
1Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
CNS neuroscience & therapeutics
|March 3, 2026
概括
药物MCC-135通过降低NCX1表达来治疗,这降低了脑中的过载和谷氨酸水平. 这项研究揭示了MCC-135的存在.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 的研究研究.
背景情况:
- 影响30%的患者对标准治疗有抗性,需要新的治疗点.
- 天体细胞和神经元中的细胞内失调与有关.
- 已注意到MCC-135的抗发作潜力,但其在的机制是未知的.
研究的目的:
- 使用计算和实验方法识别MCC-135的治疗分子标.
- 在症小鼠模型中验证MCC-135的治疗作用和机制.
主要方法:
- 单细胞分析和分子对接被用来识别MCC-135的目标.
- 为了验证,使用了一种因开氨酸 (KA) 诱导的性小鼠模型.
- 免疫光染色评估了星球细胞和神经元中的NCX1同定位.
主要成果:
- 在KA诱导的性小鼠的海马体中,NCX1表达被上调.
- 治疗MCC-135增加了发作的延迟时间,并减少了海马的损伤.
- MCC-135降低了NCX1表达,过载和谷氨酸水平.
结论:
- 通过降低NCX1.1,MCC-135显示神经保护和抗发作作用.
- 该药物可以缓解海马的过载和谷氨酸水平.
- 这项研究是首次阐明MCC-135在中的机制,提供了新的治疗见解.
相关概念视频
Antiepileptic Drugs: Calcium Channel Blockers
1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
4.4K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.4K
Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Potassium Channel Activators
867
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
867
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K


